Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Down 11.8% in January

Ikena Oncology, Inc. (NASDAQ:IKNA) saw a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 114,900 shares, a decline of 11.8% from the January 15th total of 130,200 shares. Approximately 0.6% of the company’s stock are short sold. Based on an average daily trading volume, of 226,200 shares, the short-interest ratio is presently 0.5 days.

Hedge Funds Weigh In On Ikena Oncology

Institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC bought a new stake in Ikena Oncology during the 2nd quarter valued at approximately $36,000. FMR LLC increased its position in Ikena Oncology by 94.1% in the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock worth $66,000 after buying an additional 18,607 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Ikena Oncology during the fourth quarter worth approximately $72,000. Squarepoint Ops LLC bought a new stake in shares of Ikena Oncology in the fourth quarter valued at approximately $72,000. Finally, Northern Trust Corp boosted its position in shares of Ikena Oncology by 19.7% in the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company’s stock valued at $94,000 after acquiring an additional 9,456 shares during the period. 75.00% of the stock is currently owned by institutional investors.

Ikena Oncology Trading Down 2.6 %

Shares of IKNA opened at $1.49 on Tuesday. Ikena Oncology has a one year low of $1.22 and a one year high of $1.94. The company’s fifty day moving average price is $1.55 and its 200 day moving average price is $1.65.

Analyst Ratings Changes

IKNA has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Ikena Oncology in a report on Monday, November 11th. Wedbush reaffirmed a “neutral” rating and set a $2.00 target price on shares of Ikena Oncology in a research report on Monday, December 23rd.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.